Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers

Nivolumab is the first checkpoint-inhibitor approved for the treatment of advanced HCC patients. Real-life experience data of nivolumab treatment in HCC patients, especially those with advanced liver disease, is scarce. All patients with confirmed advanced HCC and nivolumab treatment from three large German centers were retrospectively analyzed. Clinical parameters and outcome were assessed. A total of 34 patients were included. At the time of...